These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32686635)

  • 1. Methylphenidate and the risk of burn injury among children with attention-deficit/hyperactivity disorder.
    Chen VC; Yang YH; Yu Kuo T; Lu ML; Tseng WT; Hou TY; Yeh JY; Lee CT; Chen YL; Lee MJ; Dewey ME; Gossop M
    Epidemiol Psychiatr Sci; 2020 Jul; 29():e146. PubMed ID: 32686635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosage of methylphenidate and traumatic brain injury in ADHD: a population-based study in Taiwan.
    Liao YT; Yang YH; Kuo TY; Liang HY; Huang KY; Wang TN; Lee Y; McIntyre RS; Chen VC
    Eur Child Adolesc Psychiatry; 2018 Mar; 27(3):279-288. PubMed ID: 28856464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of psychiatric comorbidities with the risk of transport accidents in ADHD and MPH.
    Liu YC; Chen VC; Yang YH; Chen YL; Gossop M
    Epidemiol Psychiatr Sci; 2021 Feb; 30():e14. PubMed ID: 33583471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan.
    Shyu YC; Yuan SS; Lee SY; Yang CJ; Yang KC; Lee TL; Wang LJ
    Schizophr Res; 2015 Oct; 168(1-2):161-7. PubMed ID: 26363968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study.
    Liang SH; Yang YH; Kuo TY; Liao YT; Lin TC; Lee Y; McIntyre RS; Kelsen BA; Wang TN; Chen VC
    Res Dev Disabil; 2018 Jan; 72():96-105. PubMed ID: 29121517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
    Shyu YC; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Wang LJ
    Clin Ther; 2016 Mar; 38(3):595-602. PubMed ID: 26874787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan.
    Wang LJ; Yang KC; Lee SY; Yang CJ; Huang TS; Lee TL; Yuan SS; Shyu YC
    PLoS One; 2016; 11(8):e0161061. PubMed ID: 27518196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testicular Function After Long-Term Methylphenidate Treatment in Boys with Attention-Deficit/Hyperactivity Disorder.
    Wang LJ; Lee SY; Chou WJ; Lee MJ; Tsai CS; Lee TL; Yang CJ; Yang KC; Chen CK; Shyu YC
    J Child Adolesc Psychopharmacol; 2019 Aug; 29(6):433-438. PubMed ID: 30575416
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of negative media publicity on attention-deficit/hyperactivity disorder medication in Taiwan.
    Wang LJ; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Shyu YC
    Pharmacoepidemiol Drug Saf; 2016 Jan; 25(1):45-53. PubMed ID: 26549311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylphenidate and TBI in ADHD and co-occurring epilepsy and mental disorders: a self-controlled case series study.
    Chen VC; Yang YH; Lee CT; Chen YL; Dewey ME; Gossop M
    Eur Child Adolesc Psychiatry; 2022 Feb; 31(2):361-368. PubMed ID: 33389157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Alopecia Areata Risk in Children with Attention-Deficit/Hyperactivity Disorder and the Impact of Methylphenidate Use: A Nationwide Population-Based Cohort Study.
    Ho HY; Wong CK; Wu SY; Hsiao RC; Chen YL; Yen CF
    Int J Environ Res Public Health; 2021 Feb; 18(3):. PubMed ID: 33535410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study.
    Garbe E; Mikolajczyk RT; Banaschewski T; Petermann U; Petermann F; Kraut AA; Langner I
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):452-8. PubMed ID: 23234588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder.
    Olfson M; Marcus SC; Zhang HF; Wan GJ
    J Manag Care Pharm; 2007 Sep; 13(7):570-7. PubMed ID: 17874863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
    Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
    Liu Q; Zhang H; Fang Q; Qin L
    J Clin Exp Neuropsychol; 2017 Nov; 39(9):854-865. PubMed ID: 28052720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
    Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D
    J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use and Characteristics of Antipsychotic/Methylphenidate Combination Therapy in Children and Adolescents with a Diagnosis of Attention-Deficit/Hyperactivity Disorder.
    Scholle O; Banaschewski T; Enders D; Garbe E; Riedel O
    J Child Adolesc Psychopharmacol; 2018; 28(6):415-422. PubMed ID: 29768038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.